Monopar Therapeutics (NASDAQ:MNPR) Raised to Strong-Buy at Jones Trading

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by stock analysts at Jones Trading from a “hold” rating to a “strong-buy” rating in a note issued to investors on Friday,Zacks.com reports.

Several other research firms have also issued reports on MNPR. Lake Street Capital began coverage on shares of Monopar Therapeutics in a report on Tuesday, September 23rd. They set a “buy” rating and a $106.00 price objective on the stock. HC Wainwright set a $105.00 target price on Monopar Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 29th. Piper Sandler set a $95.00 price target on Monopar Therapeutics and gave the company an “overweight” rating in a report on Thursday, September 25th. Raymond James Financial set a $142.00 price objective on Monopar Therapeutics and gave the stock a “strong-buy” rating in a research report on Monday, October 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $103.25.

Monopar Therapeutics Stock Performance

Shares of MNPR opened at $87.82 on Friday. Monopar Therapeutics has a 1 year low of $4.50 and a 1 year high of $105.00. The company has a market cap of $541.85 million, a price-to-earnings ratio of -26.37 and a beta of 1.42. The firm has a fifty day moving average of $54.12 and a 200-day moving average of $43.31.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12. Analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling

In other Monopar Therapeutics news, Director Christopher M. Starr sold 16,800 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the director owned 5,173 shares of the company’s stock, valued at approximately $206,920. This represents a 76.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the chief executive officer owned 73,472 shares of the company’s stock, valued at $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 592,733 shares of company stock worth $36,700,227. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey acquired a new stake in Monopar Therapeutics in the second quarter valued at $34,000. AlphaQuest LLC acquired a new position in Monopar Therapeutics during the first quarter worth approximately $44,000. JPMorgan Chase & Co. raised its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics in the second quarter valued at approximately $80,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Monopar Therapeutics in the second quarter valued at approximately $104,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.